Syndax Pharmaceuticals (SNDX) Competitors

Syndax Pharmaceuticals (NASDAQ:SNDX) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability, institutional ownership, dividends and risk.

Do analysts rate SNDX or RYTM?

Syndax Pharmaceuticals currently has a consensus target price of $35.91, indicating a potential upside of 239.73%. Rhythm Pharmaceuticals has a consensus target price of $75.38, indicating a potential upside of 18.03%. Given Syndax Pharmaceuticals' higher probable upside, equities research analysts plainly believe Syndax Pharmaceuticals is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.91
Rhythm Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is SNDX or RYTM more profitable?

Syndax Pharmaceuticals has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -230.07%. Syndax Pharmaceuticals' return on equity of -64.34% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	N/A	-64.34%	-57.72%
Rhythm Pharmaceuticals	-230.07%	-367.36%	-77.47%

Which has more risk and volatility, SNDX or RYTM?

Syndax Pharmaceuticals has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 2.36, meaning that its share price is 136% more volatile than the S&P 500.

Which has higher earnings and valuation, SNDX or RYTM?

Rhythm Pharmaceuticals has higher revenue and earnings than Syndax Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$43.72M	20.80	-$209.36M	-$3.86	-2.74
Rhythm Pharmaceuticals	$136.86M	29.69	-$184.68M	-$2.81	-22.73

Does the media prefer SNDX or RYTM?

In the previous week, Syndax Pharmaceuticals had 5 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 14 mentions for Syndax Pharmaceuticals and 9 mentions for Rhythm Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 1.42 beat Rhythm Pharmaceuticals' score of 0.93 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	12 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor SNDX or RYTM?

Syndax Pharmaceuticals received 82 more outperform votes than Rhythm Pharmaceuticals when rated by MarketBeat users. However, 68.13% of users gave Rhythm Pharmaceuticals an outperform vote while only 65.22% of users gave Syndax Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Syndax Pharmaceuticals	Outperform Votes 392 65.22%	Underperform Votes 209 34.78%
Rhythm Pharmaceuticals	Outperform Votes 310 68.13%	Underperform Votes 145 31.87%

Summary

Syndax Pharmaceuticals and Rhythm Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.